कंपनी का अवलोकन
BridgeBio Pharma, Inc. is a biopharmaceutical entity dedicated to the discovery, development, and delivery of therapeutic medicines specifically designed for patients suffering from genetic diseases. The company operates within the broader Healthcare sector and focuses on the specialized industry of Biotechnology, where innovation in molecular biology drives the creation of novel treatments for rare conditions. The organization employs a workforce of 834 individuals and currently holds a market capitalization of $14.64 billion while reporting a Trailing Twelve Months revenue of $502.08 million. These financial figures indicate a significant valuation relative to its current revenue base, suggesting that the market is pricing in substantial future potential for the company's pipeline rather than current cash flows, which is a common characteristic of biotechnology firms with promising genetic disease targets but limited historical profitability.
वित्तीय स्वास्थ्य
The company reported a Trailing Twelve Months revenue of $502.08 million, yet it incurred a net income of $-724,931,008 and an EBITDA of $-496,630,016. The substantial gap between the positive revenue figure and the deeply negative net income reveals a highly aggressive cost structure where research, development, and operational expenses far exceed the revenue generated from current sales. Free cash flow stands at $-325,290,624, which indicates that the company is burning cash to fund its operations and clinical trials, implying limited immediate financial flexibility without access to external capital markets. The gross margin is reported at 95.8%, reflecting the high value added per unit in the biotechnology sector, but this is counterbalanced by an operating margin of -83.3% and a profit margin of -144.4%, highlighting that overhead and development costs are consuming the majority of the gross profit. The balance sheet shows a cash position of $587.48 million against total debt of $1.86 billion, while the debt-to-equity ratio is listed as N/A, suggesting a capital structure heavily reliant on equity financing or convertible instruments rather than traditional long-term debt. The current ratio of 2.77 indicates that the company possesses 2.77 times the current assets required to cover its short-term liabilities, pointing to a robust liquidity position despite the overall cash burn. Return on Equity and Return on Assets are both N/A due to the negative equity base, which prevents the calculation of traditional return metrics, while the Return on Assets is explicitly stated as -33.8%, revealing that management is currently utilizing assets to generate negative returns on the asset base.
मूल्यांकन आकलन
The trailing P/E ratio is N/A due to the lack of net income, while the forward P/E is an extremely high 37760.00, implying that the market is expecting a dramatic turnaround in earnings or a significant increase in stock price to justify the valuation. The price-to-book ratio is -7.05, a metric that is technically negative and indicates that the company's market value is less than the book value of its equity, often seen in biotech firms with intangible assets not fully reflected on the balance sheet. The price-to-sales ratio stands at 29.16 and the EV/EBITDA is -32.07, suggesting that investors are valuing the company primarily on its revenue potential and pipeline prospects rather than current earnings power or cash flow generation. The stock has traded within a 52-week range with a high of $84.94 and a low of $28.32, placing the current valuation context within this volatile historical band. The beta of 1.09 indicates that the stock's price volatility is slightly higher than the broader market, meaning that for every 1% move in the general market index, BBIO tends to move approximately 1.09% in the same direction.
Growth & Income
Revenue growth year-over-year is listed at 2521.2%, while earnings growth is N/A, indicating that the company is experiencing massive top-line expansion but has not yet achieved consistent profitability to support earnings growth calculations. Since the earnings growth is not calculable due to negative income, the company is clearly in a pre-profitability phase where revenue expansion outpaces the ability to generate net income. As a non-dividend payer, the company maintains a dividend yield of N/A and a payout ratio of 0.0%, meaning that all available earnings are theoretically reinvested into research, development, and operational growth rather than being distributed to shareholders. This profile characterizes BridgeBio Pharma as a classic growth-stage biotechnology company that relies on reinvestment of capital and external funding to advance its pipeline of genetic disease therapies rather than providing current income to investors.